Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | ||
Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn | |||
Zytram XL | Tramadol hydrochloride | Pain, acute | Do not list | Complete | ||
Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
Mekinist | Trametinib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Ogivri | Trastuzumab | Withdrawn | ||||
TBD | Trastuzumab | Cancelled |